What Alisma Treats: Main Uses and Benefits

Alisma is a specialized therapeutic option commonly used for women who require both effective contraception and supportive management of specific symptoms related to hormonal activity. The primary benefit provides support that helps ease the overall burden of visible, persistent, and often distressing androgen-dependent manifestations. This combination medicine is generally used to help manage symptoms associated with severe, chronic acne, significant excessive unwanted hair growth (hirsutism), and excessively oily skin (seborrhoea).

The medicine is commonly applied in clinical contexts involving hyperandrogenism, often associated with conditions like Polycystic Ovary Syndrome (PCOS). This supports the easing of these manifestations and supports functional stability, particularly through assisting in addressing menstrual cycle fluctuations.

The medicine is relevant in clinical scenarios where the patient requires a single, dedicated therapy to fulfill two needs simultaneously: effective pregnancy prevention and supportive relief for persistent skin or hair issues. This approach contributes to general well-being during symptomatic phases.

“Alisma is used when groups of androgen-related symptoms appear together and interfere with daily comfort, offering supportive relief for these distressing manifestations.”

Quick Fact: Support for Androgen Symptoms
Primary Symptoms Managed: Severe acne, hirsutism, and seborrhoea.
Context of Use: Dual need for effective contraception and symptom support.
Patient Benefit: Contributes to easing visible skin manifestations and helps ease the overall symptom load.

Regulatory References

1. European Medicines Agency (EMA) guidance

Eligibility Map: Who can and cannot use Alisma — official regulatory information

This section details the formal eligibility and non-eligibility criteria for Alisma (cyproterone acetate/ethinyl estradiol) as established in official government regulatory documents.

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Women of reproductive age, specifically after menarche and before menopause.

Populations for whom use is contraindicated:

• Individuals with a history of or current thromboembolic disorders (e.g., deep vein thrombosis, stroke, myocardial infarction) or a known hereditary thrombogenic predisposition.
• Patients with a meningioma or history of meningioma.
• Patients with active liver disease or previous/existing liver tumours (benign or malignant).
• Women with known or suspected sex-steroid influenced malignancies (e.g., breast cancer).
• Pregnant or lactating women, and men.
• Individuals using any other hormonal contraceptive.

Eligibility-related Restrictions:

• Use for acne is strictly conditional and limited to cases where topical therapy or systemic antibiotic treatments have failed.
• Contraindicated in cases of severe diabetes mellitus with vascular changes or severe hypertension.
• Smoking women over 35 years old are strongly discouraged from use due to significantly increased cardiovascular risk.

Interactions with other medicines and products

The official regulatory profile for Alisma details specific combinations that are strictly prohibited and outlines pharmacokinetic effects arising from co-administration with other substances. This information is derived exclusively from governmental product labeling.

Formal Contraindications

Co-administration with other hormonal contraceptives is strictly prohibited to avoid excessive hormonal exposure. The use of Alisma is also formally contraindicated alongside specific Hepatitis C regimens containing ombitasvir, paritaprevir, and ritonavir due to the documented risk of elevated liver enzymes (ALT elevations).

Exposure-Altering Interactions

The efficacy of Alisma may be reduced when taken with agents that stimulate hepatic metabolism. These enzyme-inducing agents include specific anticonvulsants (such as phenytoin and carbamazepine), rifamycins, and the herbal product St. John's wort. This interaction results in a reduced plasma concentration of Alisma's active components. Conversely, Alisma may alter the clearance of several co-administered medicines, potentially changing the plasma levels of agents like corticosteroids and certain beta blockers.

Conditions and Procedures

Acute gastrointestinal disturbances, such as vomiting or severe diarrhoea, are noted conditions that may interfere with the full absorption of the tablets, potentially reducing efficacy. Additionally, the medicine is documented to interfere with the results of certain laboratory tests, including those used to measure clotting factors and thyroid function.

How Alisma Works at the Biological Level

---

Modulation of Lipid and Cholesterol Metabolism

Active components of Alisma bind as agonists to nuclear receptors including Farnesoid X Receptor (FXR) and Peroxisome Proliferator-Activated Receptor alpha (PPARalpha) . This interaction modulates hepatic gene expression, leading to a suppression of de novo lipogenesis and promotion of lipid export from the liver, resulting in the modification of systemic cholesterol and triglyceride ratios.

---

Regulation of Inflammation and Oxidative Stress Pathways

Alisma compounds engage mechanisms that suppress the NF-kappaB and MAPK signaling pathways, key cascades involved in the inflammatory response. Simultaneously, the drug influences the expression of Antioxidant enzymes, thereby attenuating oxidative stress. This action on inflammatory mediators like TNF-alpha and reactive oxygen species contributes to the modulation of cellular stress responses.

---

Influencing Energy Sensing and Autophagic Flux

Alisma's components engage mechanisms that influence the AMPK/NAMPT/SIRT1 signaling axis. This modulation affects the rate of cellular energy substrate turnover and contributes to structural maintenance processes, specifically by promoting cholesterol homeostasis and influencing the activation of mitophagic flux (clearance of damaged mitochondria).

Administration Overview

Alisma, derived from the tubers of Alisma plantago-aquatica (water plantain), is traditionally prepared and consumed in various forms within herbal practices. Its application is typically determined by the specific tradition and the intended use of the botanical material.

Common Preparations

Decoctions

The most frequent method of preparation involves boiling the dried, sliced rhizomes in water. This process extracts the water-soluble constituents, such as certain triterpenes and polysaccharides. The resulting liquid is strained and typically consumed while warm.

Powders and Capsules

Dried Alisma rhizomes may be ground into a fine powder. This powder can be mixed into water or other liquids, or encapsulated for easier consumption. This form is often used when a standardized quantity of the raw plant material is required.

Processing Methods (Pao Zhi)

In traditional contexts, Alisma is rarely used in its raw state. It often undergoes specific processing techniques to alter its perceived properties:

• Salt-Processing: The rhizomes are often fried with a salt-water solution, a method believed to influence how the substance interacts with specific internal systems.
• Bran-Frying: Roasting the sliced rhizomes with wheat bran is another common preparation intended to moderate the botanical's characteristics.

Considerations for Use

When utilizing Alisma, the focus is generally on consistency in preparation and the quality of the raw material. The timing of consumption—whether before or after meals—may vary based on traditional recommendations or the specific form of the preparation being used.

Research Evidence / Overview of Studies for Alisma

The research on Alisma (Cyproterone acetate / Ethinyl estradiol) has focused on its systemic action for contraception and its evaluation for use in managing persistent symptoms linked to male hormone activity, specifically in women of reproductive age. The research base includes Randomized Controlled Trials (RCTs), comparative studies, and long-term surveillance data that inform regulatory guidance.

---

Evidence for Managing Severe Acne

Alisma was studied for the management of moderate to severe acne. Research examined outcomes linked to inflammatory or irritative states. The populations studied often included individuals with acne that was associated with hormonal influences, such as some cases of Polycystic Ovary Syndrome (PCOS). Studies used standardized measures like total lesion counts and the Investigator’s Global Assessment (IGA) score to monitor symptom patterns over defined time intervals.

The findings describe patterns observed in the studies over follow-up durations that were typically short to medium-term. Research highlights measured changes during the study period, including outcomes related to quantified symptom assessments. Evidence of limited consistency in the exact grading tools used across all studies has been documented. There is limited information for long-term outcomes regarding the persistence of these changes after treatment discontinuation.

---

Evidence for Managing Moderate to Severe Hirsutism

Alisma was evaluated in women experiencing moderate to severe excessive unwanted hair growth (hirsutism). Research examined outcomes related to systemic or functional imbalance by monitoring quantified hair scores. Studies focused on episodes where symptoms become more noticeable and required long follow-up durations. The findings indicate that studies monitored patterns of change in objective scores during the observed periods.

Comparative evidence against certain other anti-androgen treatments was observed in some studies, but these findings were sometimes based on small populations. The evidence quality varies across studies, and the certainty remains low for some head-to-head comparisons, partly because sample sizes were modest.

---

What is Still Uncertain About the Research

The overall evidence highlights areas where the certainty of findings may be influenced by documented research limitations. Data for certain groups remain insufficient, and comparative evidence is sometimes lacking in long-term head-to-head trials against newer treatments. The results apply only to the populations studied, meaning research does not determine whether an individual outside the study criteria will respond similarly. Findings describe group patterns, and research provides context but not individual predictions.

Key Studies & References Anti-androgen treatment in women with acne: a controlled trial

Common questions about Alisma (FAQ)

Q: What is Alisma?

A: Alisma, often referred to by the botanical name Alisma orientale (or Alisma plantago-aquatica subsp. orientale), is a perennial aquatic plant whose dried rhizome has a long history of use in Traditional Chinese Medicine (TCM). In TCM, it is known as Ze Xie.

Q: What is Alisma traditionally used for?

A: In traditional systems, Alisma is commonly used for conditions associated with water metabolism. It has been historically used to:

• Promote urination and address reduced urine output.
• Help manage the retention of excess fluid (edema).
• Address conditions like painful urination and turbid urine, which traditional practices may attribute to "damp heat."

Q: Is there scientific evidence supporting the traditional uses of Alisma?

A: Limited scientific evidence from human clinical trials currently exists. Research has primarily involved in vitro (cell culture) and animal studies (e.g., mice and rats). These early studies suggest that extracts from Alisma may exhibit various biological activities, including effects on water balance, lipid metabolism, and markers of inflammation.

Q: What compounds are in Alisma?

A: The key chemical constituents isolated from the Alisma rhizome are generally categorized as triterpenoids (e.g., Alisol B 23-acetate) and sesquiterpenoids. These compounds are thought to be responsible for the plant's observed biological activities in research settings.

Q: What does research indicate regarding Alisma and liver health?

A: Pre-clinical research, mainly involving animal models and cell studies, has suggested that Alisma extract may be associated with beneficial effects related to non-alcoholic fatty liver disease (NAFLD) and related conditions. Specifically, research has observed an association with:

• Reduced hepatic fat accumulation in animal models.
• Modulation of certain markers related to lipid (fat) and glucose metabolism.
• Anti-inflammatory activity in cell lines.

Q: Is Alisma considered a safe and effective treatment for any medical condition?

A: No. The available scientific data is not sufficient to conclusively confirm that Alisma is safe or effective for treating any specific medical condition in humans according to modern medical standards. Its efficacy is primarily rooted in centuries of traditional use, not in high-quality, large-scale human clinical trial evidence. More research is needed before any definitive health-related claims can be made.

Q: How should I take Alisma?

A: This content does not provide dosing instructions or medical advice. You must consult with a qualified healthcare professional before starting any new herbal supplement, including Alisma, to discuss potential benefits, risks, and appropriate use.

How to Store and Dispose of Alisma

The official storage and handling instructions for Alisma (cyproterone acetate/ethinyl estradiol) are designed to maintain product integrity and stability.

Storage Requirements

Alisma tablets must be stored at a temperature below 25°C and should be kept in a cool and dry place. To prevent degradation, the product must be protected from direct sunlight.

The medication must remain in its original package (carton and blister) until use, and should not be taken after the expiry date printed on the packaging. For child safety, it is a mandatory requirement to keep this medicine out of the sight and reach of children.

Disposal Rules

Regulatory labeling dictates that unused or expired Alisma must not be thrown away via wastewater or household waste. Users are instructed to ask a pharmacist how to properly dispose of the medicine. This ensures compliance with environmental protection guidelines for pharmaceutical waste.